Benjamin
The Living Force
Today the Canadian gov. approves Pfizer's anti-viral Paxlovid for use:
www.cp24.com
Paxlovid consists of two medicines: nirmatrelvir (150 mg- protease inhibitor) and ritonavir (100 mg- antiviral, aka: Norvir, used to treat HIV/Aids and Hep C).
In the fact sheets from Pfizer (covid19oralrx.com/en):
For a grand total of 30 tablets= 20 nirmatrelvir (3000 mg) and 10 ritonavir (1000 mg).
So if you are not at high risk for progression will they just give it to you anyway? Do they even care what happens?

Canada approves Pfizer's COVID-19 oral antiviral treatment for adults
Health Canada added another tool to its pandemic-fighting arsenal Monday, approving Pfizer's antiviral treatment for COVID-19 as the rapid spread of the Omicron variant continued to tax the country's health-care system and millions of students returned to in-person learning.
Paxlovid consists of two medicines: nirmatrelvir (150 mg- protease inhibitor) and ritonavir (100 mg- antiviral, aka: Norvir, used to treat HIV/Aids and Hep C).
In the fact sheets from Pfizer (covid19oralrx.com/en):
Take 2 pink tablets of nirmatrelvir with 1 white tablet of ritonavir by mouth 2 times each day (in the morning and in the evening) for 5 days. For each dose, take all 3 tablets at the same time.
For a grand total of 30 tablets= 20 nirmatrelvir (3000 mg) and 10 ritonavir (1000 mg).
PAXLOVID is investigational because it is still being studied. There is limited information about the safety and effectiveness of using PAXLOVID to treat people with mild-to-moderate COVID-19.
The FDA has authorized the emergency use of PAXLOVID for the treatment of mild-to- moderate COVID-19 in adults and children [12 years of age and older weighing at least 88 pounds (40 kg)] with a positive test for the virus that causes COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death, under an EUA.
So if you are not at high risk for progression will they just give it to you anyway? Do they even care what happens?
Last edited: